BACKGROUND: Hemocompatibility-related clinical adverse events (HRAEs) are major causes of readmission in patients with left ventricular assist devices (LVADs). Omega-3 is an unsaturated fatty acid that possesses anti-inflammatory and antiangiogenic properties. We aimed to investigate the impact of omega-3 therapy on HRAEs during LVAD support. METHODS: Consecutive LVAD patients who were followed for 6 months were enrolled, and stratified by the use of omega-3. Freedom from any HRAEs and net burden of HRAEs, which was calculated by using a hemocompatibility score (using 4 escalating tiers of hierarchal severity to derive a total score for events), were compared between those with and without omega-3 therapy. RESULTS: Among 169 LVAD patients (57 years old and 124 males), 31 patients received 4 g/d of omega-3 therapy and 138 patients were in the control group. During the 6-month observational period, freedom from any HRAEs was 90% in the omega-3 group compared with 70% in the control group with a hazard ratio of 0.35 (95% confidence interval 0.11-0.87 and P = .042). The average hemocompatibility score in the omega-3 group was significantly lower compared with the control group (0.23 vs 0.91; P = .042), due to reduced Tier I scores (mild HRAE; P = .003) and Tier IIIB scores (severe HRAE; P < .001). The similar trends remained at propensity-matched populations. CONCLUSIONS: Omega-3 therapy was associated with reduced HRAEs including both bleeding and thromboembolic events in LVAD patients.
BACKGROUND: Hemocompatibility-related clinical adverse events (HRAEs) are major causes of readmission in patients with left ventricular assist devices (LVADs). Omega-3 is an unsaturated fatty acid that possesses anti-inflammatory and antiangiogenic properties. We aimed to investigate the impact of omega-3 therapy on HRAEs during LVAD support. METHODS: Consecutive LVADpatients who were followed for 6 months were enrolled, and stratified by the use of omega-3. Freedom from any HRAEs and net burden of HRAEs, which was calculated by using a hemocompatibility score (using 4 escalating tiers of hierarchal severity to derive a total score for events), were compared between those with and without omega-3 therapy. RESULTS: Among 169 LVADpatients (57 years old and 124 males), 31 patients received 4 g/d of omega-3 therapy and 138 patients were in the control group. During the 6-month observational period, freedom from any HRAEs was 90% in the omega-3 group compared with 70% in the control group with a hazard ratio of 0.35 (95% confidence interval 0.11-0.87 and P = .042). The average hemocompatibility score in the omega-3 group was significantly lower compared with the control group (0.23 vs 0.91; P = .042), due to reduced Tier I scores (mild HRAE; P = .003) and Tier IIIB scores (severe HRAE; P < .001). The similar trends remained at propensity-matched populations. CONCLUSIONS:Omega-3 therapy was associated with reduced HRAEs including both bleeding and thromboembolic events in LVADpatients.
Authors: Ivan Netuka; Peter Ivák; Zuzana Tučanová; Stanislav Gregor; Ondrej Szárszoi; Poornima Sood; Daniel Crandall; Jessica Rimsans; Jean Marie Connors; Mandeep R Mehra Journal: J Heart Lung Transplant Date: 2018-04-11 Impact factor: 10.247
Authors: Nir Uriel; Paolo C Colombo; Joseph C Cleveland; James W Long; Christopher Salerno; Daniel J Goldstein; Chetan B Patel; Gregory A Ewald; Antone J Tatooles; Scott C Silvestry; Ranjit John; Christiano Caldeira; Valluvan Jeevanandam; Andrew J Boyle; Kartik S Sundareswaran; Poornima Sood; Mandeep R Mehra Journal: Circulation Date: 2017-04-06 Impact factor: 29.690
Authors: Christopher T Sparrow; Michael E Nassif; David S Raymer; Eric Novak; Shane J LaRue; Joel D Schilling Journal: JACC Heart Fail Date: 2015-11-11 Impact factor: 12.035
Authors: Mandeep R Mehra; Yoshifumi Naka; Nir Uriel; Daniel J Goldstein; Joseph C Cleveland; Paolo C Colombo; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Ulrich P Jorde; Francis D Pagani; Keith D Aaronson; David A Dean; Kelly McCants; Akinobu Itoh; Gregory A Ewald; Douglas Horstmanshof; James W Long; Christopher Salerno Journal: N Engl J Med Date: 2016-11-16 Impact factor: 91.245